The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Análisis farmacoeconómico de la pentoxifilina en úlceras venosas
Open accessAbstract
El tratamiento con pentoxifilina oral es el tratamiento sistémico más estudiado para la resolución médica de las úlceras venosas y asociado a compresión ha demostrado ser más efectivo que la compresión aislada. Evaluar la eficiencia de 1.200 mg/día de pentoxifilina más vendaje compresivo en el tratamiento de las úlceras venosas. Evaluación económica mediante un análisis de coste-efectividad. Los comparadores fueron la compresión combinada con el tratamiento oral con 1.200 mg/día de pentoxifilina y la terapia de ‘sólo compresión’. El ámbito de análisis fue el de la actuación ambulatoria en España y se consideraron dos horizontes temporales distintos para realizar la comparación, las 8 y las 24 semanas. La perspectiva del análisis fue la del Servicio Nacional de Salud. La asignación de probabilidades se realizó con datos de los ensayos clínicos publicados. A las ocho semanas se cura el 33,33% de los pacientes con la terapia combinada y el 22,22% del grupo de terapia ‘sólo con compresión’. La terapia combinada resulta ser más coste-efectiva o eficiente, y el ratio coste-efectividad incremental (ICER) es de 282,1. A las 24 semanas con terapia combinada se cura un 63,31% de los pacientes frente al 45,39% con la terapia de ‘sólo con compresión’. La terapia combinada se mantiene como la más eficiente y resulta un ICER de 524,7. A través de los análisis de sensibilidad se comprueba que el modelo es robusto y que las conclusiones del análisis se mantienen frente a variaciones en el porcentaje de cura (entre un mínimo de 5 y un máximo de 10 puntos porcentuales) y en el coste de la cura de más de 9 euros. El tratamiento asociado, vendaje compresivo más tratamiento farmacológico con 1.200 mg/día de pentoxifilina, además de más eficaz, es más coste-efectivo que el tratamiento de ‘sólo con compresión’ realizado en la terapia de las úlceras venosas. The treatment with oral pentoxifylline is the most studied systemic treatment for the medical resolution of the venous ulcers. Moreover, when combined with compression, it has been proved to be more effective than the compression alone. To assess the efficiency of 1,200 mg/day of pentoxifylline plus a compressive bandage in the treatment of the venous ulcers. Economic assessment through a cost-effectivity analysis. The comparators were the combined treatment of 1,200 mg/day of pentoxifylline plus compression therapy and the compression therapy alone. The scope of this study was out-patient treatment in Spain and the patients were assessed after both 8 and 24 weeks of treatment. The perspective of the analysis was that of the National Health Service. Model probabilities were obtained from published clinical trials. At 8 weeks, 33.33% of patients using combined treatment were cured, versus 22.22% of the patients treated ‘only with compression’. The most cost-effective or efficient regimen was the combined treatment with an incremental cost-effectivity ratio (ICER) of 282.1. At 24 weeks, 63.31% of the patients using the combined treatment were cured, versus 45.39% of the patients treated ‘only with compression’. Again the most cost-effective regimen was the combined treatment, this time with an ICER of 524.7. The sensitivity analyses performed show the robustness of the model and present conclusions are still valid for changes in the effectiveness of a minimum of 5 and a maximum of 10 percentual points. Also we can lower the cost of the cure material more than 9 euros without changing the most efficient regimen. The combined regimen, compressive therapy plus a pharmacological treatment with 1,200 mg/day of pentoxifylline, in addition to being more effective, is more cost-effective than the ‘;compressive treatment alone’ when treating venous ulcers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Highsmith, W. E., Burch, L. H., Zhou, Z., Olsen, J. C., Boat, T. E., Spock, A., Gorvoy, J. D., Quittell, L., Friedman, K. J., Silverman, L. M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311503 · Cited by 441
Cited by
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,094
Mutations of the Cystic Fibrosis Gene in Patients with Chronic Pancreatitis
Sharer, N., Schwarz, M., Malone, G., Howarth, A., Painter, J., Super, M., & Braganza, J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809033391001 · Cited by 954
Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896
Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
An Investigation into Causative Factors in Patients with Bronchiectasis
PASTEUR, M. C., HELLIWELL, S. M., HOUGHTON, S. J., WEBB, S. C., FOWERAKER, J. E., COULDEN, R. A., FLOWER, C. D., BILTON, D., & KEOGAN, M. T. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.4.9906120 · Cited by 684
Metadata
- Authors
- Marinel·lo-Roura, J., Iglesias-García, C., Lorenzo-Ferrer, J., Mercadal-Dalmau, J., & Lozano-Fernández de Pinedo, R.
- Venue
- Angiología
- Publisher
- ARAN Ediciones
- Published
- 2007-01
- Volume
- 59
- Issue
- 1
- Pages
- 45-54
- ISSN
- 0003-3170 (ISSN-L)
- OpenAlex
- W1909128047
- Cited by
- 174
- References
- 2
- FWCI
- 5.20
- Type
- journal article
- Language
- es
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Análisis farmacoeconómico de la pentoxifilina en úlceras venosas. https://app.cochat.ai/papers/10.1016/s0003-3170(07)75026-5
- The paper
- Marinel·lo-Roura, J., Iglesias-García, C., Lorenzo-Ferrer, J., Mercadal-Dalmau, J., & Lozano-Fernández de Pinedo, R. (2007). Análisis farmacoeconómico de la pentoxifilina en úlceras venosas. Angiología. https://doi.org/10.1016/s0003-3170(07)75026-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.